Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$1,812 Mln
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-242.71 Mln
EBITDA
$-389.78 Mln
Net Profit
$-345.11 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ProKidney Corp (PROK)
| -53.20 | -19.59 | -52.07 | -70.92 | -- | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
2024
|
2023
|
|
|---|---|---|
|
ProKidney Corp (PROK)
| -5.02 | -74.05 |
|
BSE Sensex
| 8.10 | 18.74 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells... (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Address: 2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103 Read more
Founder
Dr. Timothy A. Bertram D.V.M., Ph.D.
Founder
Dr. Timothy A. Bertram D.V.M., Ph.D.
Headquarters
Winston-Salem, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ProKidney Corp (PROK) is $0.79 (NASDAQ) as of 17-Apr-2025 16:00 EDT. ProKidney Corp (PROK) has given a return of -70.92% in the last 1 years.
ProKidney Corp (PROK) has a market capitalisation of $ 1,812 Mln as on 17-Apr-2025. As per Value Research classification, it is a company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ProKidney Corp (PROK) and enter the required number of quantities and click on buy to purchase the shares of ProKidney Corp (PROK).
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Address: 2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103
The CEO & director of Dr. Timothy A. Bertram D.V.M., Ph.D.. is ProKidney Corp (PROK), and CFO & Sr. VP is Dr. Timothy A. Bertram D.V.M., Ph.D..
There is no promoter pledging in ProKidney Corp (PROK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| ProKidney Corp. (PROK) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ProKidney Corp (PROK) was $0 Mln.
$-0.01
(
